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Abstract
Background:  Cough  capacity  derangement  is  associated  with  a  high  risk  of  pulmonary
complications  in  amyotrophic  lateral  sclerosis  patients  when  cough  assistance  is  not  routinely
performed  at  home.  The  primary  aim  of  this  study  was  to  evaluate  the  feasibility  of  a  long-term
home based  daily  self-monitoring  cough  capacity.
Methods:  Eighteen  subjects  were  enrolled  in  a  9-month  study  at  home.  Changes  in  peak  cough
expiratory ﬂow,  oxygen  saturation,  respiratory  discomfort  and  incidence  of  respiratory  deteri-
oration events  were  evaluated.  In  subjects  presenting  respiratory  deterioration  events,  decline
in the  abovementioned  respiratory  variables  was  evaluated  (#NCT00613899).
Results:  During  an  average  follow-up  of  125  ±  102  days,  a  total  of  1175  measures  were  per-
formed on  12  subjects.  Mean  compliance  to  proposed  evaluations  was  37  ±  32%  which  worsened
over time.  Peak  cough  expiratory  ﬂow  decreased  by  15.08  ±  32.43  L/min  monthly.  Five  sub-
jects reported  6  episodes  of  respiratory  deterioration  events,  after  a  mean  period  of  136  ±
108 days.  They  had  poor  respiratory  function  and  more  years  of  disease.  There  was  no  dif-
ference in  peak  cough  expiratory  ﬂow  and  its  decline  whether  subjects  presented  respiratory
deterioration  events  or  not.  In  4  subjects  the  respiratory  discomfort  score  signiﬁcantly  worsened
after respiratory  deterioration  events  from  3.0  ±  1.41  to  4.25  ±  1.71.
Conclusion:  Daily  self-monitoring  of  peak  cough  expiratory  ﬂow,  oxygen  saturation  and  respira-
tory discomfort  seems  difﬁcult  to  obtain  because  of  poor  adherence  to  measures;  this  protocol
does not  seem  to  add  anything  to  current  practice  of  advising  on  clinical  derangements.  Con-
ﬁrmatory larger  studies  are  necessary.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
 The study was performed at Fondazione Salvatore Maugeri IRCCS Lumezzane (BS) Italy.
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Estudo-piloto  de  monitorizac¸ão domiciliária  da  capacidade  de  tosse  na  esclerose
lateral  amiotróﬁca:  série  de  casos
Resumo
Antecedentes:  A  disfunc¸ão  na  capacidade  de  tosse  está  associada  a  um  elevado  risco  de
complicac¸ões pulmonares  nos  doentes  com  esclerose  lateral  amiotróﬁca,  quando  a  sua
monitorizac¸ão não  é  realizada  rotineiramente  no  domicílio.  O  objetivo  principal  deste  estudo
foi avaliar  a  viabilidade  de  uma  automonitorizac¸ão  domiciliária  diária  da  capacidade  da  tosse,
a longo  prazo.
Métodos:  Dezoito  doentes  foram  incluídos  num  estudo  com  durac¸ão  de  9  meses,  realizado  no
domicílio.  Foram  avaliadas  as  alterac¸ões  do  débito  expiratório  máximo  da  tosse,  a  saturac¸ão
de oxigénio,  o  desconforto  respiratório  e  a  incidência  de  eventos  de  deteriorac¸ão  respiratória.
Em doentes  que  apresentavam  eventos  de  deteriorac¸ão  respiratória,  foi  avaliada  a  diminuic¸ão
nas variáveis  respiratórias  supracitadas  (#NCT00613899).
Resultados:  Durante  um  acompanhamento  médio  de  125  ±  102  dias,  foram  realizadas  um  total
de 1.175  medic¸ões  em  12  doentes.  A  média  de  cumprimento  para  as  avaliac¸ões  propostas
foi de  37  ±  32%,  e  piorou  ao  longo  do  tempo.  O  débito  expiratório  máximo  da  tosse  dimin-
uíu em  15,08  ±  32,43  L/min  mensalmente.  Cinco  doentes  relataram  6  episódios  de  eventos  de
deteriorac¸ão respiratória,  após  um  período  médio  de  136  ±  108  dias.  Tinham  uma  func¸ão  respi-
ratória mais  alterada  e  mais  anos  de  doenc¸a.  Não  existia  diferenc¸a  no  débito  expiratório  máximo
da tosse  e  na  sua  diminuic¸ão,  quer  os  sujeitos  apresentassem  eventos  de  deteriorac¸ão  respi-
ratória ou  não.  Em  4  doentes  o  resultado  de  desconforto  respiratório  piorou  signiﬁcativamente
após os  eventos  de  deteriorac¸ão  respiratória,  de  3,0  ±  1,41  para  4,25  ±  1,71.
Conclusão:  A  auto  monitorizac¸ão  diária  diária  do  débito  expiratório  máximo  da  tosse,  da
saturac¸ão de  oxigénio  e  do  desconforto  respiratório  parecem  difíceis  de  obter  devido  à  fraca
adesão a  sua  determinac¸ão;  este  protocolo  parece  nada  acrescentar  à  prática  atual  de  acon-
selhamento  sobre  os  distúrbios  clínicos.  É  no  entanto  necessária  a  conﬁrmac¸ão  deste  resultado
em estudos  posteriores  com  amostras  de  maior  dimensão.
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ntroduction
eterioration  of  respiratory  function  is  a  critical  factor
n  amyotrophic  lateral  sclerosis  (ALS).1 Respiratory  tract
nfections  (RTIs)  are  the  principal  causes  of  morbidity  and
ortality.2 Low  level  of  peak  cough  expiratory  ﬂow  (PCEF)
s  associated  with  a  high  risk  for  pulmonary  complications
uring  RTIs,3--5 for  hospisalization,6 and  is  also  considered
n  indicator  for  spontaneous  cough  effectiveness  during  an
cute  RTI.6--8 PCEF  reﬂects  the  capacity  to  expulse  debris
rom  the  airways  (cough  efﬁcacy)  and  values  less  than
60  L/min  are  associated  with  extubation  failure.9
After  RTIs,  subjects  with  neuromuscular  diseases  have
 slow  recovery  of  clinical,  functional  and  oxygenation
arameters.3
Studies  have  also  demonstrated  the  importance  of  using
peciﬁc  cough  assistance  techniques9--13 in  order  to  avoid
ehospitalisation.4,11,14--18
Although  easily  evaluable,  PCEF  is  not  routinely  done  at
ome  in  subjects  with  ALS.
The  primary  aim  of  this  study  was  to  evaluate,  in  sub-
ects  with  non-bulbar  ALS,  the  feasibility  of  a  long-term
9  months),  home-based,  comprehensive  protocol  involving
aily  self-monitoring  for  cough  capacity.  Changes  in  objec-
ive  (PCEF  and  SpO2 )  and  subjective  (respiratory  discomfort
RD])  respiratory  variables,  occurrence  of  respiratory  dete-
ioration  events  (RDEs)  and  inﬂuence  of  baseline  PCEF  and
ts  decline  during  time  on  RDEs  were  evaluated  as  secondary
utcomes.
s
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ubjects
ubjects  with  diagnosis  of  ALS  according  to  the  El  Esco-
ial  criteria,19 admitted  to  the  Rehabilitation  Respiratory
ivision  of  Fondazione  S.  Maugeri  --  Lumezzane  (BS),  were
onsidered  for  this  study.  Inclusion  criteria  were:  (1)  ALS
unctional  rating  scale  (ALS-FRS-R)  score  <  35,  (2)  non-bulbar
mpairment  at  ﬁrst  presentation  deﬁned  by  clinical  pre-
entation  and  a  PCF/PEF  (peak  espiratory  ﬂow)  ratio  >  1,
3)  PCEF  <  450  L/m,  (4)  NIV  prescription  at  home.  Criteria
or  starting  NIV  were  daytime  hypercapnia,  sleep-related
ypoxemia,  and  decrease  of  vital  capacity  below  50%
redicted.20 Exclusion  criteria  were  refusal,  tracheostomy,
o  caregiver  availability,  dementia,  bulbar  patients.  The
tudy  was  approved  by  the  Technical  and  Scientiﬁc
ommittee  of  our  Institute.  All  subjects  gave  informed
onsent.
easures
t  baseline  the  following  tests  or  evaluations  were  car-
ied  out:  (a)  anthropometric  characteristics,  (b)  ALS-FRS-R
core,  (c)  respiratory  function  (FEV1, FVC,  FEV1/FVC,  VC,
IP,  MEP)  according  to  Quanier  predictive  indices,21 (d)  arte-
ial  blood  gases  (ABG),  (e)  mechanical  ventilation  use,22
f)  PCEF  measured  at  rest  using  a  peak  ﬂow  meter
ophic  lateral  sclerosis  183
Table  1  Anthropometric  and  functional  characteristics  of
12 patients  with  ALS  (and  caregivers)  at  hospital  discharge.
Variables  Values
Age,  years  (mean  ±  SD)  53  ±  10
Male/female,  %  75/25
Years  of  disease,  n  (mean  ±  SD)  3.4  ±  1.9
ALS FRS-R  (mean  ±  SD)  20.2  ±  6.8
NIV users,  n  7
FEV1,  %  predicted  (mean  ±  SD) 75  ±  29
FVC, %  predicted  (mean  ±  SD) 74  ±  30
FEV1/FVC  (mean  ±  SD) 85  ±  11
VC, %  predicted  (mean  ±  SD) 75  ±  31
MIP, %  predicted  (mean  ±  SD)  34  ±  17
MEP, %  predicted  (mean  ±  SD)  34  ±  13
PaO2 ,  mmHg  (mean  ±  SD)  82  ±  13
PaCO2 ,  mmHg  (mean  ±  SD) 42  ±  9
pH (mean  ±  SD) 7.42  ±  0.05
SpO2 ,  %  (mean  ±  SD) 95.50  ±  1.58
PCEF,  L/min  (mean  ±  SD) 290  ±  72
Respiratory  discomfort  (Borg
scale,  mean  ±  SD)
2.92  ±  1.31
Caregivers  age,  y  (mean  ±  SD)  49  ±  11
Time spent  by  caregivers,  h/day
(mean  ±  SD)
18.6  ±  5.6
Type  of  caregiver,  %
Wife/husband  66
Brother/sister  5
Son/daughter  16
Professional  caregiver  5
Other  8
ALS FRS-R: amyotrophic lateral sclerosis functional rating scale
revised; FEV1: forced expiratory volume at ﬁrst second; FRS:
functional rating scale; FVC: forced vital capacity; MEP: maximal
expiratory pressure; MIP: maximal inspiratory pressure; PaO2 :
pressure partial pressure of oxygen in arterial blood; PaCO2 : pres-
sure partial pressure of carbon dioxide in arterial blood; PCEF:
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(Mini-Wright,  standard  range  peak  ﬂow  meter  Clement
Clarke  International,  UK)  connected  to  a  face  mask  (Ultra-
seal,  Ambu  A/S  DK-2750  Ballerup  Denmark).  The  patients
will  have  to  be  kept  in  sitting  and  asked  to  cough  as  forcibly
as  possible  (an  unassisted  cough  manoeuvre).  The  maximum
observed  ﬂows  in  four  or  ﬁve  attempts  were  recorded.23
All  subjects  could  generate  peak  cough  ﬂows  because,  at
that  time,  they  were  able  to  close  the  glottis,  to  air  stack.
Socio-demographic  characteristics  of  caregiver  and  hours  of
care/day  were  also  recorded.
Protocol
Subjects  received  a  pulse  oximeter  (NONIN  Onyx® 9500  Fin-
gertip  Pulse  Oximeter,  Nonin  Medical,  INC.  Plymouth,  MN,
USA)  a  peak  ﬂow  meter  with  mask,  a  Borg  scale  sheet,
and  a  clinical  diary  to  be  ﬁlled  in.  None  of  the  subjects
received  mechanical  cough  assistance  devices  at  home.
During  their  stay  at  home,  subjects  were  informed  that
they  would  receive  telephonic  support  from  a  dedicated
physiotherapist  (PT)  during  working  hours  on  a  bi-weekly
basis.  At  home,  the  patient/caregiver  was  requested,  in  the
early  morning  and  nocturnal  application  of  NIV  on  a  daily
basis  to  measure:  (a)  pulsed  arterial  saturation,  (b)  PCEF,
(c)  subjective  respiratory  discomfort  (RD)  using  a  Borg  scale
(0  =  absolute  well-being,  no  symptoms,  10  =  maximum  sen-
sation  of  discomfort).23 The  subjects  were  asked  to  record
on  a  diary  card,  each  morning,  any  change  in  respiratory
and  clinical  condition  and  evidence  of  RDE  deﬁned  as:  acute
respiratory  derangement  with  unresolved  desaturation  <  95%
despite  patients  independently  trying  to  revert  desatura-
tions  by  increasing  NIV16 (when  prescribed)  and  assisted
coughing  techniques,  fever  with  intercurrent  respiratory
tract  infection,  need  to  increase  time  of  NIV  >16  h/day,
severe  secretion  encumbrance  with  antibiotic  prescription,
signiﬁcant  increase  (>5  sessions/day)  of  manual  assisted
coughing  techniques  with  air-stacking,  urgent  call  out  of
family  doctor,  access  to  Emergency  Room  with  or  without
need  for  hospitalisation.
At the  end  of  each  patient’s  follow-up  period,  the  follow-
ing  data  were  collected:  days  of  follow-up,  number  of  RDEs,
monthly  decline  in  PCEF.  In  subjects  presenting  RDEs,  val-
ues  of  PCEF,  SpO2 and  RD  at  three  ﬁxed  time  points  −16  days
before  a  RDE,  the  day  before  a  RDE  and  30  days  after  RDE
starting  or  after  30  days  since  ER  or  hospitalisation  event
were  concurrently  evaluated.
Good  adherence  to  the  protocol  was  deﬁned  when
patients  performed  at  least  50%  of  prescribed  daily  protocol
measurements.
Statistical  analysis
Data  were  evaluated  by  statistical  software  STATA  11.2.
PCEF  decline  was  calculated  as  the  difference  between
the  last  available  PCEF  value  and  the  pre-discharge  PCEF
value;  monthly  decline  was  calculated  as  the  whole
decline/number  of  months  of  follow-up  for  each  patient.
A  patient  with  high/low  PCEF  monthly  decline  was  deﬁned
as  a  patient  with  a  value  higher  or  lower  than  the  median
value  of  monthly  decline.  A  -square  Pearson  test  was  used
to  compare  the  groups  with  or  without  RDEs  in  subjects  with
d
A
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1peak cough expiratory ﬂow; SpO2 : oxygen saturation; VC: vital
capacity.
igh  or  low  decline,  and  PCEF  >  or  <270  L/min.  One-way
NOVA  test  was  conducted  among  values  of  PCEF,  SpO2 and
org  measured  16  days  before,  the  day  before  a  RDE
nd  30  days  after  a  RDE  and,  post  hoc  analysis  by  Tukey  Test
as  performed,  if  Fisher  test  was  signiﬁcant.  Comparison
f  baseline  continuous  variables  was  conducted  by  Wilcoxon
est  in  subjects  with  and  without  RDE.  Compliance  with  the
aily  protocol  measurements  was  deﬁned  as  the  ratio  of  the
umber  of  performed  measurements  divided  by  the  total
rescribed  measurements  (maximum  #  =  270).
esults
rom  April  2009  to  July  2012,  18  subjects  with  ALS  who  met
ligibility  criteria  were  identiﬁed.  Four  subjects  refused  to
articipate  and  two  subjects  withdrew  consent.  Therefore,
ata  for  12  subjects  were  analysed  (66.7%  of  acceptance).
nthropometric,  functional  and  ABG  data  at  baseline  are
hown  in  Table  1.  During  an  average  period  of  follow-up  of
25  ±  102  days  (range  21--270),  the  12  subjects  performed
184  M.  Paneroni  et  al.
Table  2  Differences  in  baseline  data  according  to  patients  with  or  without  respiratory  deterioration  events  (RDEs).
Parameters  RDEs  group  (n  =  5)  No  RDEs  group  (n  =  7)  p
Age,  years  51  ±  5  54  ±  12
Male, %  71  80  NS
FEV1,  %  predicted  59.00  ±  27.76  91.20  ±  21.99  0.0472
FVC, %  predicted  56.00  ±  28.13  88.83  ±  22.85  NS
FEV1/FVC  89.75  ±  11.73  79.75  ±  8.01  NS
VC, %  predicted 59.40  ±  31.03  86.71  ±  27.93  NS
MIP, %  predicted  (mean  ±  SD) 29.60  ±  16.11 37.14  ±  18.11 NS
MIP, cmH2O 31  ±  14.71 40.5  ±  24.75 NS
MEP, %  predicted  (mean  ±  SD) 33.20  ±  10.21 32.57  ±  14.75 NS
MEP, cmH2O  61.25  ±  15.10  61.25  ±  17.69  NS
PCEF, L/min  276  ±  80  286  ±  43  NS
PaO2 ,  mmHg  78.40  ±  18.19  84.66  ±  3.49  NS
PaCO2 ,  mmHg  42.00  ±  13.09  41.74  ±  3.68  NS
pH 7.43  ±  0.08 7.42  ±  0.01 NS
Years of  diseases,  years 4.60  ±  1.52 2.58  ±  1.72 0.0384
PCEF month/decline,  L/min 26.45  ±  33.88 6.95  ±  31.28 NS
Follow-up,  days 150.4  ±  92.95 107.42  ±  111.6 NS
ALS FRS-R,  score  18.4  ±  0.87  19.28  ±  3.42  NS
ALS FRS-R: amyotrophic lateral sclerosis functional rating scale revised; FEV1: forced expiratory volume at ﬁrst second; FRS: functional
rating scale; FVC: forced vital capacity; MEP: maximal expiratory pressure; MIP: maximal inspiratory pressure; NIV: non invasive venti-
lation; PaO2 : pressure partial pressure of oxygen in arterial blood; PaCO2 : pressure partial pressure of carbon dioxide in arterial blood;
a
a
w
2
D
d
t
b
a
a
t
i
c
e
n
a
t
m
d
s
h
e
w
f
R
s
n
8
c
a
d
a
−
d
r
w
e
s
<
a
b
s
3
p
t
f
4
O
(
9
4
d
n
D
PPCEF: peak cough expiratory ﬂow.
Data are expressed as mean ± SD.
 total  of  1175  measures.  The  total  compliance  for  all
bovementioned  parameters  was  37  ±  32%  (range  8--100%)
orsening  across  time  from  63  ±  27%  (at  months  1--3)  to
6  ±  39%  (at  months  3--6),  and  (22  ±  35%)  at  months  6--9.
uring  the  study,  the  subjects  sent  data  reported  on  the
iary  mainly  by  e-mail  (69%).
16%  of  subjects  delivered  data  by  personal  contact,  and
he  remaining  provided  over  telephone.  58%  of  subjects,
ecause  of  delay  in  delivery,  had  to  be  followed  up  by  phone
t  least  once  by  PT  and  they  performed  PCEF  with  caregiver
ssistance.
One  patient  (8%)  presented  clinical  instability  not  related
o  respiratory  causes.  Five  out  of  the  12  subjects  stud-
ed  (42%)  reported  six  episodes  of  RDEs:  one  episode  of
hest  infection  with  fever  needing  antibiotics  at  home,  three
pisodes  of  desaturation  and  disturbed  sleep  with  urgent
eed  to  also  increase  time  of  NIV  during  the  day  without
ny  change  in  NIV  setting,  one  episode  of  severe  secre-
ion  encumbrance  with  activation  of  more  frequent  use  of
anual  assisted  cough  manoeuvres  without  any  change  in
evice  setting  (repetitive  two  hours  application  for  36  con-
ecutive  hours),  one  episode  of  respiratory  failure  needing
ospitalisation  and  need  for  24  h  NIV  use.  Two  consecutive
pisodes,  both  due  to  urgent  need  to  increase  time  of  NIV,
ere  reported  by  the  same  patient  after  21  and  92  days
rom  the  start  of  the  study.  The  mean  time  before  the  ﬁrst
DE  was  136  ±  108  days  (range  21--255  days).  None  of  the
ubjects  received  mechanical  cough  assistance  devices  or
eeded  tracheostomy  during  RDEs.  Hospitalisation  rate  was
.3%  while  none  was  admitted  to  ER  and  immediately  dis-
harged.
Table  2  shows  differences  in  pre-discharge  baseline  data
ccording  to  subjects  with  or  without  RDEs:  among  all  these
i
e
ﬂata,  subjects  with  RDEs  showed  a  statistically  worse  FEV1
nd  more  years  of  disease  duration.
The  overall  decline  in  PCEF  during  the  study  was
46.25  ±  68.37  L/min  (range  30--190).  Level  of  monthly
ecline  in  PCEF  was  −15.08  ±  32.43  (median  value  7.53;
ange  30--85.5)  L/min.  In  our  series,  the  lower  level  of  PCEF
as  40  L/min  and  the  minimum  SpO2 was  90%.  No  differ-
nces  were  found  in  subjects  with  or  without  RDEs  between
ubjects  with  high  or  low  decline  (p  <  0.079),  PCEF  >  or
270  L/min  (p  <  0.276).
Subjects  with  high  and  low  PCEF  decline  did  not  differ
t  the  start  of  the  project  for  any  of  the  baseline  varia-
les.  Individual  trends  and  values  in  PCEF,  SpO2 and  RD  at
peciﬁc  time  points  (16  days  before,  at  the  RDEs  start  and
0  days  after  RDEs)  were  available  in  4  out  of  5  subjects
resenting  an  RDE  (80%)  (Fig.  1).  ANOVA  analysis  shows
hat  the  sensation  of  discomfort  only  worsened  signiﬁcantly
rom  16  days  before  and  30  days  after  from  3.0  ±  1.41  to
.25  ±  1.71  points  of  Borg  score  (Tukey  Test  signiﬁcant).
n  the  day  of  the  RDE,  these  subjects  had  worsened  PCEF
from  225  ±  69.5  L/min  to  177.5  ±  42.7  L/min),  SpO2 (from
5  ±  1.83  to  93  ±  0%)  and  subjective  RD  (from  2.25  ±  0.96  to
.75  ±  1.89  Borg  score)  with  respect  to  their  pre-discharge
ata.  These  changes  however  did  not  reach  statistical  sig-
iﬁcance.
iscussion
revious  studies  have  shown  that  PCEF  is  a  good  functional
ndicator  of  spontaneous  cough  effectiveness.6--8
Home  patients’  diaries  have  been  proposed  for  COPD
xacerbation24--27 while  home  variation  in  peak  expiratory
ow  has  been  evaluated  in  asthma28,29 and  COPD.30
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Figure  1  Individual  trends  and  values  in  PCEF,  SpO2 and  respi-
ratory  discomfort  by  Borg  scale  16  days  before,  the  day  before
and  30  days  after  four  RDEs  related  to  respiratory  causes
in 4  representative  subjects.  Borg  scale  detected  wellbeing
respiratory  sensation  (0  =  absolute  wellbeing,  no  symptoms,
10 =  maximum  perceived  feeling  of  discomfort).
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tPCEF  indicates  peak  cough  expiratory  ﬂow;  SpO2 ,  oxygen  satu-
ration as  measured  by  pulse  oxymetry.
Sancho  et  al.6 reported  that  ALS  subjects  received  a
home  protocol  based  on  scheduled  clinical  and  functional
assessment  by  a  physician  and  were  encouraged  to  request
hospitalisation  if  they  suffered  dyspnoea,  ineffective  cough
or  decreased  oxyhemoglobin  saturation.6
A  signiﬁcant  decrease  of  sniff  nasal  inspiratory  pressure
(SNIP)  and  a  parallel  increase  in  dyspnoea  Borg  Score  were
observed  in  14  ALS  subjects  during  a  period  of  19  months.31
Baseline  dyspnoea  index  was  found  to  be  related  with  a
decline  in  forced  vital  capacity  which  was  better  than  that
of  the  revised  ALS  functional  rating  scale  (ALS-FRS-R)  and  a
visual  analogue  scale.2
Compliance  with  the  proposed  protocol  was  not  high;
it  was  67%  before  discharge  and  it  got  worse  over  time;
this  result  is  very  similar  to  the  compliance  with  home
d
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CEF  monitoring  in  subjects  with  asthma.32 Two  main  rea-
ons  can  be  identiﬁed:  the  long  duration  of  the  study  and
he  huge  number  of  measurements  requested  daily.  Psycho-
ogical  and  depressive  reasons  might  have  further  reduced
dherence.
In  regards  to  the  feasibility  of  conducting  the  protocol  at
ome,  it  is  interesting  to  note  that  the  adherence  to  the  pro-
ocol  deteriorated,  especially  after  the  ﬁrst  three  months,
nd  that  telephone  feedback  by  the  physiotherapist  became
ecessary.  Moreover,  subjects  sent  their  data  through  the
ail  thinking  that  this  method  was  simpler  and  more  reli-
ble.  In  more  than  half  of  the  cases  caregivers  performed  the
equired  measurements:  this  is  not  surprising  since  ALS  is  a
evere  disabling  disease  requiring  a  high  amount  of  caring
y  caregivers.
More  than  40%  of  subjects  presented  6  episodes  of  respi-
atory  derangements.  Five  subjects  presenting  a  RDE  were,
n  general,  more  compromised  in  all  functional  and  clini-
al  parameters.  Also  the  decline  during  follow-up  was  worse
han  that  of  subjects  without  RDE.
Due  to  the  small  sample  size,  statistical  signiﬁcance  was
nly  found  for  FEV1 and  years  of  diseases.  It  is  also  interest-
ng  to  note  that  a  cut  off  of  baseline  PCEF  >  or  <  to  270  L/min
as  not  predictable  for  RDEs.
Previous  results  from  literature  do  not  show  what
ould  happen  to  these  subjects  during  a  respiratory  tract
nfection.18 Only  Poponick  et  al.3 evaluated  respiratory  func-
ion  in  subjects  with  multiple  muscular  dystrophies  during
nd  in  the  post  recovery  phase  of  acute  upper  respiratory
ract  infection:  whereas  we  monitored  respiratory  function,
pO2 and  cough  ability  before,  during  and  for  a  longer  post
ecovery  phase  in  a  more  homogeneous  ALS  population.
As  demonstrated  in  4  representative  subjects  (Fig.  1)
nly  the  sensation  of  discomfort  worsened  signiﬁcantly  from
6  days  before  and  30  days  after  the  RDEs  demonstrating
hat  objective  data  present  a  faster  recovery  time  than  sub-
ective  ones.
Our  pilot  data  do  not  support  the  hypothesis  that  subjects
ith  ALS  with  low  or  high  decline  in  PCEF  during  time  and
igh  or  low  level  of  baseline  PCEF  are  prone  to  have  a  RDE.
The  strengths  of  this  study  are:  (a)  proposal  for  a  home
aily  cough  capacity  follow-up,  (b)  information  on  monthly
rends  in  PCEF  decline,  (c)  documentation  of  events  during
 RDE  and  during  recovery  time.
An  important  limitation  to  this  study  is  the  small  sam-
le  size  of  the  population:  as  a  descriptive  case-series  we
eed  to  temper  our  interpretation  of  presented  data.  Poor
rotocol  adherence  prevents  deﬁnitive  conclusions  as  we
eed  to  consider  that  non-adherent  patients  could  be  the
atients  with  the  worst  disease  decline.  We  cannot  exclude
he  possibility  that  a  simpler  and  less  cumbersome  proto-
ol  (monitoring  variables  less  frequently,  monitoring  fewer
ariables  and  simplifying  the  reporting)  would  improve
atient  compliance.
In conclusion,  in  subjects  with  ALS,  good  adherence  to
ombined  daily  self-monitoring  for  PCEF,  SpO2 and  respiratory
iscomfort  seems  difﬁcult  to  obtain  and  does  not  add  fur-
her  advantages  to  current  practices  of  advising  on  clinical
erangements;  that  is  use  of  mechanical  cough  assistance
r  increase  of  ventilatory  support  immediately  SpO2 drops
elow  95%.  Conﬁrmatory  larger  studies  are  necessary  in  this
eld  in  order  to  study  new  domiciliary  monitoring  tools  and
1t
e
E
P
d
w
c
M
C
f
t
s
i
R
o
s
i
C
T
A
T
s
m
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
286  
o  ﬁnd  predicted  clinical  variables  of  respiratory  distress
vents.
thical disclosures
rotection  of  human  and  animal  subjects.  The  authors
eclare  that  the  procedures  followed  were  in  accordance
ith  the  regulations  of  the  relevant  clinical  research  ethics
ommittee  and  with  those  of  the  Code  of  Ethics  of  the  World
edical  Association  (Declaration  of  Helsinki).
onﬁdentiality  of  data.  The  authors  declare  that  they  have
ollowed  the  protocols  of  their  work  center  on  the  publica-
ion  of  patient  data  and  that  all  the  patients  included  in  the
tudy  received  sufﬁcient  information  and  gave  their  written
nformed  consent  to  participate  in  the  study.
ight  to  privacy  and  informed  consent.  The  authors  have
btained  the  written  informed  consent  of  the  patients  or
ubjects  mentioned  in  the  article.  The  corresponding  author
s  in  possession  of  this  document.
onﬂicts of interest
he  authors  have  no  conﬂicts  of  interest  to  declare.
cknowledgements
he  Authors  thanks  Laura  Comini  for  editing  and  critical  revi-
ion  and  Alessandro  Bettini  for  the  English  revision  of  the
anuscript.
eferences
1. Gay PC, Westbrook PR, Daube JR, Litchy WJ, Windebank AJ,
Iverson R. Effects of alterations in pulmonary function and sleep
variables on survival in subjects with amyotrophic lateral scle-
rosis. Mayo Clin Proc. 1991;66:686--94.
2. Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Hos-
pitalization in amyotrophic lateral sclerosis: causes, costs, and
outcomes. Neurology. 2001;56:53--7.
3. Poponick JM, Jacobs I, Supinski G, Di Marco AF. Effect of upper
respiratory tract infection in subjects with neuromuscular dis-
ease. Am J Respir Crit Care Med. 1997;156 2 Pt 1:659--64.
4. Bach JR. Amyotrophic lateral sclerosis: prolongation of life by
noninvasive respiratory AIDS. Chest. 2002;122:92--8.
5. Senent C, Golmard JL, Salachas FC¸, Chiner E, Morelot-Panzini
C, Meninger V, et al. A comparison of assisted cough tech-
niques in stable subjects with severe respiratory insufﬁciency
due to amyotrophic lateral sclerosis. Amyotroph Lateral Scler.
2011;12:26--32.
6. Sancho J, Servera E, Díaz J, Marín J. Predictors of ineffec-
tive cough during a chest infection in subjects with stable
amyotrophic lateral sclerosis. Am J Respir Crit Care Med.
2007;175:1266--71.
7. Bach JR, Gonc¸alves MR, Páez S, Winck JC, Leitão S, Abreu P.
Expiratory ﬂow maneuvers in subjects with neuromuscular dis-
eases. Am J Phys Med Rehabil. 2006;85:105--11.
8. Suárez AA, Pessolano FA, Monteiro SG, Ferreyra G, Capria ME,
Mesa L, et al. Peak ﬂow and peak cough ﬂow in the evalua-
tion of expiratory muscle weakness and bulbar impairment in
subjects with neuromuscular disease. Am J Phys Med Rehabil.
2002;81:506--11.
2M.  Paneroni  et  al.
9. Bach JR, Saporito LR:. Criteria for extubation and tracheostomy
tube removal for patients with ventilatory failure: a different
approach to weaning. Chest. 1996;110:1566--71.
0. Bach JR, Bianchi C, Vidigal-Lopes M, Turi S, Felisari G. Lung
inﬂation by glossopharyngeal breathing and ‘‘air stacking’’
in Duchenne muscular dystrophy. Am J Phys Med Rehabil.
2007;86:295--300.
1. Bach JR. Mechanical insufﬂation--exsufﬂation. Comparison of
peak expiratory ﬂows with manually assisted and unassisted
coughing techniques. Chest. 1993;104:1553--62.
2. Tzeng AC, Bach JR. Prevention of pulmonary morbidity for sub-
jects with neuromuscular disease. Chest. 2000;118:1390--6.
3. Chatwin M, Ross E, Hart N, Nickol AH, Polkey MI, Simonds AK.
Cough augmentation with mechanical insufﬂation/exsufﬂation
in subjects with neuromuscular weakness. Eur Respir J.
2003;21:502--8.
4. Vitacca M, Comini L, Assoni G, Fiorenza D, Gilè S, Bernocchi
P, et al. Tele-assistance in subjects with amyotrophic lateral
sclerosis: long term activity and costs. Disabil Rehabil Assist
Technol. 2012;7:494--500.
5. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy: pro-
longation of life by noninvasive ventilation and mechanically
assisted coughing. Am J Phys Med Rehabil. 2002;81:411--5.
6. Bach JR, Bianchi C, Auﬁero E. Oximetry and indications
for tracheotomy for amyotrophic lateral sclerosis. Chest.
2004;126:1502--7.
7. Vitacca M, Trainini D, Bianchi L, Assoni G, Saleri M, Gilè S, et al.
At home and on demand mechanical cough assistance program
for subjects with amyotrophic lateral sclerosis. Am J Phys Med
Rehabil. 2010;89:401--6.
8. Servera E, Sancho J, Gómez-Merino E, Briones ML, Vergara P,
Pérez D, et al. Non-invasive management of an acute chest
infection for a patient with ALS. J Neurol Sci. 2003;209:111--3.
9. Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of
Neurology Research Group on Motor Neuron Diseases. El Esco-
rial revisited: revised criteria for the diagnosis of amyotrophic
lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron
Disord. 2000;1:293--9.
0. Vitacca M, Vianello A, on behalf of the Scientiﬁc Group on
Respiratory Intensive Care of the Italian Association of Hospi-
tal Pulmunologists. Respiratory outcomes of patients with ALS:
an Italian nationwide survey. Respir Care. 2013;58:1433--41.
1. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver
BH, et al. ERS Global Lung Function Initiative. Multi-ethnic
reference values for spirometry for the 3--95-yr age range:
the global lung function 2012 equations. Eur Respir J.
2012;40:1324--43.
2. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannac-
cone ST, et al., American Thoracic Society. Respiratory care of
the patient with Duchenne muscular dystrophy: ATS consensus
statement. Am J Respir Crit Care Med. 2004;170:456--65.
3. Borg GA. Psychophysical bases of perceived exertion. Med Sci
Sports Exerc. 1982;14:377--81.
4. Vijayasaratha K, Stockley RA. Reported and unreported
exacerbations of COPD: analysis by diary cards. Chest.
2008;133:34--41.
5. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S,
EXACT-PRO Study Group. Standardizing measurement of chronic
obstructive pulmonary disease exacerbations. Reliability and
validity of a patient-reported diary. Am J Respir Crit Care Med.
2011;183:323--9.
6. Woolhouse IS, Hill SL, Stockley RA. Symptom resolution assessed
using a patient directed diary card during treatment of acute
exacerbations of chronic bronchitis. Thorax. 2001;56:947--53.
7. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha
JA. Early therapy improves outcomes of exacerbations of
chronic obstructive pulmonary disease. Am J Respir Crit Care
Med. 2004;169:1298--303.
ophi
3Pilot  study  for  home  monitoring  of  cough  capacity  in  amyotr
28. Frey U. Predicting asthma control and exacerbations: chronic
asthma as a complex dynamic model. Curr Opin Allergy Clin
Immunol. 2007;7:223--30.
29. Frey U, Suki B. Complexity of chronic asthma and chronic
obstructive pulmonary disease: implications for risk
assessment, and disease progression and control. Lancet.
2008;372:1088--99.
30. Muskulus M, Slats AM, Sterk PJ, Verduyn-Lunel S. Fluctua-
tions and determinism of respiratory impedance in asthma
3c  lateral  sclerosis  187
and chronic obstructive pulmonary disease. J Appl Physiol.
2010;109:1582--91.
1. Just N, Bautin N, Danel-Brunaud V, Debroucker V, Matran R,
Perez T. The Borg dyspnoea score: a relevant clinical marker of
inspiratory muscle weakness in amyotrophic lateral sclerosis.
Eur Respir J. 2010;35:353--60.
2. Côté J, Cartier A, Malo JL, Rouleau M, Boulet LP. Compliance
with peak expiratory ﬂow monitoring in home management of
asthma. Chest. 1998;113:968--72.
